secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001104659-26-034928
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood provides HALT-CINP trial update; $12.5M raised, SP16 IND filed
----------------------------------------------------------------------

- 145 patients recruited in Halneuron Phase 2b HALT-CINP study; final data expected fall 2026.
- Raised $12.5M in Q1 2026; combined with year-end cash extends runway through data release.
- Filed IND for SP16 IV (chemo-induced neuropathy); Phase 1b fully funded by NCI grant.
- Advanced synthetic Halneuron formulation for Phase 3; aims to cut costs and boost yields.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000110465926034928/0001104659-26-034928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000110465926034928/dwtx-20260326x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-034928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer